Impact of pharmacological treatment for heart failure after myocardial recovery in arrhythmia-induced cardiomyopathy.

Back

ESC Professional Premium Access

Impact of pharmacological treatment for heart failure after myocardial recovery in arrhythmia-induced cardiomyopathy.

Session: Pharmacological therapy in heart failure (2)

Topic: Pharmacotherapy

Speaker: Mr L. Dominguez Rodriguez (Vigo, ES)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Mr Luis Manuel Dominguez Rodriguez

Hospital Universitario Alvaro Cunqueiro, Vigo (Spain)

1 presentation

0 follower

6 more presentations in this session

Initiation, titration, and discontinuation - utilization of heart failure medicines in England (EVOLUTION HF UK)

Speaker: Doctor R. Zhang (London, GB)

Statin and risk of dementia in patients with heart failure

Speaker: Mrs Q. Ren (Hong Kong, HK)

Soluble guanylate cyclase in heart failure: A network meta-analysis and subgroup analyses of reduced and preserved ejection fraction.

Speaker: Doctor M. Ibrahim (Flint, US)

Feasibility, efficacy and safety of early and rapid initiation of evidence-based treatment for patients with HFrEF- a real world experience of the "four drugs in four weeks" strategy

Speaker: Doctor S. Sze (Leicester, GB)

Timing of angiotensin receptor-neprilysin inhibitor initiation in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry

Speaker: Professor L. Lund (Stockholm, SE)

Access the full session

Pharmacological therapy in heart failure (2)

Speakers: Mr L. Dominguez Rodriguez, Doctor R. Zhang, Mrs Q. Ren, Doctor M. Ibrahim, Doctor S. Sze...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Impact of pharmacological treatment for heart failure after myocardial recovery in arrhythmia-induced cardiomyopathy.

About the speaker

Mr Luis Manuel Dominguez Rodriguez

6 more presentations in this session

Initiation, titration, and discontinuation - utilization of heart failure medicines in England (EVOLUTION HF UK)

Statin and risk of dementia in patients with heart failure

Soluble guanylate cyclase in heart failure: A network meta-analysis and subgroup analyses of reduced and preserved ejection fraction.

Feasibility, efficacy and safety of early and rapid initiation of evidence-based treatment for patients with HFrEF- a real world experience of the "four drugs in four weeks" strategy

Timing of angiotensin receptor-neprilysin inhibitor initiation in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry

Access the full session

Pharmacological therapy in heart failure (2)

About the event

ESC Congress 2023

ESC 365 is supported by